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Highlights 
 Those with MS who walk unaided use alternate EE and step count strategies. 
 Day type does not affect daily step count and daily EE in those with MS who walk 
unaided. 
 2 days is required for a reliable daily step count in those with MS who walk unaided. 
 4 days is required for a reliable daily EE value in those with MS who walk unaided. 
 
 
Abstract 
Background and purpose: The purpose of this study was to examine the minimum number 
of days needed to reliably estimate daily step count and energy expenditure (EE), in people 
with multiple sclerosis (MS) who walked unaided. 
Methods: Seven days of activity monitor data were collected for 26 participants with MS 
(age = 44.5 ± 11.9 years; time since diagnosis = 6.5 ± 6.2 years; Patient Determined Disease 
Steps = ≤ 3). Mean daily step count and mean daily EE (kcal) were calculated for all 
combinations of days (127 combinations), and compared to the respective 7-day mean daily 
step count or mean daily EE using intra-class correlations (ICC), the Generalizability Theory 
and Bland-Altman.  
Results: For step count, ICC values of 0.94 – 0.98 and a G-coefficient of 0.81 indicate a 
minimum of any random 2-day combination is required to reliably calculate mean daily step 
count. For EE, ICC values of 0.96 – 0.99 and a G-coefficient of 0.83 indicate a minimum of 
any random 4-day combination is required to reliably calculate mean daily EE. For Bland-
Altman analyses all combinations of days, bar single day combinations, resulted in a mean 
bias within ± 10%, when expressed as a percentage of the 7-day mean daily step count or 
mean daily EE.  
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Conclusions: A minimum of 2 days for step count and 4 days for EE, regardless of day type, 
is needed to reliably estimate daily step count and daily EE, in people with MS who walk 
unaided. 
 
Keywords:  Accelerometry, chronic disease, physical activity, pedometry.  
 
 
Introduction  
 
Multiple sclerosis (MS) is a chronic autoimmune disease which can result in symptoms such 
as fatigue, depression, loss of mobility, balance and coordination, and neurological 
dysfunction [1-3]. These symptoms have an overall impact on activities of daily living (ADL) 
and physical functioning [4], and therefore any treatment and/or intervention which may 
lessen the impact of these symptoms may improve overall quality of life (QOL) in people 
with MS [5]. 
 
One such treatment is engaging in regular physical activity (PA) [6]. Recently the numerous 
health benefits of PA participation, such as reduced risk of sedentary related disease onset 
[7], increased muscular strength [7], and increased psychological wellbeing [8], have been 
found among people with MS [9-12]. However, current research [13-17] indicates that people 
with MS are substantially more inactive than their non-diseased counterparts.  
 
The accurate selection of objective measures of PA are vital to a better understanding of PA 
and MS [18]. PA has previously been defined as “any bodily movement produced by skeletal 
muscles that result in EE” and therefore accelerometer outputs of both step count and energy 
expenditure may be useful ways of estimating free living PA [19]. The use of step count as an 
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output is consistent with the use of walking as a primary monitoring outcome of PA in MS 
research due to its link with disease progression and disability level [20, 21]. Research [22] 
has found that accelerometers measure both PA and walking mobility in people with MS, 
whilst also providing an objective measurement outcome sensitive to detecting differences in 
PA [1]. Furthermore, accelerometer step count has been found to be a reliable measure of PA 
in people with MS [23]. Additionally, people with MS may use activity modifications, such 
as a decrease in step count, to conserve EE when performing everyday activities [24]. 
Therefore, EE is also a parameter of interest when investigating PA levels in people with MS. 
 
When measuring step count or EE in a free-living environment the number of days required 
for monitoring is of importance to ensure a reliable estimate of the variable of interest is 
collected [18, 23]. People with MS already have significant constraints on everyday living 
due to MS symptoms; therefore PA measurement should be for as short a possible time as to 
be accurate, while not overly impacting on the person’s life. Whilst a 7-day monitoring 
period is commonly used to assess PA in people with MS [25], monitor wearing compliance 
has ranged from one to seven days [26]. Previous research [23] has investigated the number 
of days of pedometer monitoring required to accurately predict daily step count in adults with 
multiple sclerosis, indicating a minimum of 3 days is necessary. However, it was unclear how 
many participants performed habitual walking behaviour aided or un-aided. People with MS 
who perform gait unaided are of particular interest as they are typically the targets of PA 
interventions, and undertake habitual walking behaviour similar to a non-diseased population, 
whilst concurrently managing the symptoms of MS. Also, whilst previous research [23] 
recommended a 3-day monitoring period, this cannot be assumed when measuring PA 
utilising EE as a monitoring outcome, as people with MS adopt alternate EE and step count 
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strategies when performing the same task [24]. In doing so people with MS may slow down 
the pace at which they move, or in fact move less.    
       
Lastly, in previous research [23] pedometers and accelerometers utilised to measure step 
count and/or EE were not worn 24 hours a day. This may lead to missed data due to non-wear 
time. Also, gait behaviour within an MS population can fluctuate from day-to-day, and from 
one time of a day to another [27]. Therefore, to achieve a thorough reflection of step count 
and EE in MS population, participants should wear the chosen accelerometer or pedometer 
for all waking hours. The SenseWear Armband© (SWA) can be worn 24 hours a day and is 
lightweight and unobtrusive during ADL's. The SWA has been identified to provide adequate 
step count data in people with MS and a valid estimate of EE during everyday activities [28]. 
For this reason, the SWA has achieved many of the recommendations previously set forward 
for capturing walking behaviour and EE in people with MS [27]. 
 
To this end, the purpose of this study was to investigate the minimum number of days needed 
to reliably estimate daily step count and EE, using the SWA, in people with MS who walk 
unaided. 
 
 
Methods 
 
 
Data utilised within this study was collected via the “Step It Up” [29] study protocol within a 
larger randomised controlled trial study. The study was performed in agreement with the 
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Declaration of Helsinki and approved by the Health Service Executive Mid-West Research 
Ethics Committee, the Galway University Hospitals Clinical Research Ethics Committee and 
the University of Limerick, Faculty of Education and Health Sciences Research Ethics 
Committee. 
 
 
Participants and Protocol 
 
 
Participants completing the “Step It Up” [29] research study were recruited via (1) social 
media, email and postal communications of the MS Society of Ireland and (2) via neurology 
clinics in three urban locations in the west and south of Ireland. Participants which expressed 
interest were screened for selection criteria. Inclusion criteria included: (1) physician-
confirmed formal diagnosis of MS, (2) aged 18 years or more, (3) Patient Determined 
Disease Steps score of ≤ 3 (participant has gait disability, but can work entire day [30]), (4) a 
sedentary lifestyle (<30 minutes of moderate to strenuous exercise one day or more per week 
over the last six months) and (5) willing to give written informed consent. Exclusion criteria 
included: (1) pregnancy, (2) MS relapse in the last 12 weeks and (3) changes to MS 
medication or steroid treatment in the last 12 weeks. This resulted in SWA data for a total of 
68 participants, all of which undertook one of two 10- week exercise based interventions. 
Whilst numerous outcome measures were recorded within the “Step It Up” [29] protocol, for 
this analysis only daily step count and daily EE recorded over a 7-day period pre- 
intervention (week 1) were utilised. Daily step count and daily EE data were recorded via the 
SWA, which participants were asked to wear day and night for a 7-day period. For the current 
analysis SWA step count and EE data were visually screened post data collection and only 
7 
 
participants with 7 valid days of step count and EE data were included. A valid day was a 24 
hour period in which there were 10+ hours of awake, recorded SWA activity, criteria 
previously used within MS populations [31]. Awake hours were identified as the hours 
between two extended periods of sedentary behaviour (typically 6 to 10 hours), in which a 
participant displayed both step count and EE data for a minimum of 30 minutes. Therefore, 
due to SWA failure (n = 4) and participants not having 7 valid days of step count and EE data 
(n = 38), a total of 26 participants were included in the final analysis (age = 44.5 ± 11.9 
years). Participants in the final sample had been diagnosed with MS for 6.5 ± 6.2 years and 
the majority had relapsing –remitting MS (relapsing –remitting, n = 21; benign, n = 2; 
primary progressive, n = 1; secondary progressive, n = 1; unknown, n = 1).  
 
Additionally, the SWA provides two measures of EE. The first EE measure is the conversion 
of counts, via prediction equations, to metabolic equivalents (METs). The second EE 
measure is kilocalories per day (kcals per day). Within this study EE was estimated using 
kcals per day as Coote and O'Dwyer [28] found that kilocalorie estimates provided a more 
accurate estimate of PA than METS, using the SWA, in people with MS performing ADL’s.  
 
Lastly, preceding the main investigation the 7 valid days of step count and EE data collected 
were categorised by day type (Monday – Sunday) and analysed to investigate if there was a 
significant difference in daily step count or daily EE due to day type. Within this preceding 
analysis, 1 of the 26 participants with 7 valid days had two re-occurring days (i.e. Monday 
twice), due to non-consecutive SWA wear. This participant was therefore omitted from the 
preceding investigation (n = 25). 
 
Data Analysis 
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Data analysis methods are similar to those previously used [23, 32, 33] and therefore are 
summarised below. For the preceding investigation daily step count and daily EE over the 7-
day period was calculated for those only with 7 consecutive valid days representing Monday 
– Sunday (n = 25). A one-way repeated measures analysis of variance (ANOVA) was 
performed to investigate if a significant difference lay in daily step count or daily EE, due to 
day type, across the 7-day period. Hereafter, analysis was performed on all participants with 
7 valid, consecutive and non-consecutive days (n = 26).  Coefficient of Variance (CoV) was 
used to calculate daily step count and daily EE variability within participant (CoVw) and 
between participants (CoVb), expressed as a percentage. Mean daily step count and mean 
daily EE were calculated for all possible day combinations (1 day to 7 day combinations), 
resulting in 127 mean daily values for each parameter (step count and EE). A two way 
random effects model was utilised for intra-class correlations (ICCS’s) calculation between 
all possible mean daily step counts and mean daily EE values from all combinations of days, 
compared to criterion mean daily step count and mean daily EE derived from the valid 7-day 
period. All statistical analysis was conducted using SPSS version 21.0. Furthermore, the 
minimum number of days needed to calculate a reliable estimate of mean daily step count and 
mean daily EE was estimated in MATLAB™ (Mathworks, Cambridge, UK) utilising the 
Generalizability Theory [34]. Explained in detail elsewhere [34], briefly within the 
Generalizability Theory firstly we performed an extended two-way repeated measures 
ANOVA (G-study) in which the amount of variance contributed by each factor (participant 
and day) and the interaction effect (participant × day) were outlined. Secondly, G-coefficients 
were calculated using a fully crossed D-study design (participant × day) to derive the 
minimum number of days needed to calculate a reliable estimate of mean daily step count and 
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mean daily EE. For both ICC values and G-coefficients, following previous literature [23, 32, 
33], a threshold of 0.80 was utilised as the minimum cut-off to calculate the reliable amount 
of days needed. Lastly, a comparison of methods was assessed by calculating the paired 
difference of the methods, and the mean of the methods [35]. The criterion method was the 
mean daily step count and mean daily EE derived from the 7-day period, while the 
comparison methods were the mean daily step count and mean daily EE values derived from 
single and multiple day combinations (n = 127 for each parameter). Bland-Altman plots 
provide mean bias values (criterion – comparison) and 95% confidence intervals (95% CI = ± 
1.96 × SD) [36]. These were calculated in both standard units (steps and kcal) and also as a 
percentage of the criterion and represented in table format.  
 
 
Results 
 
There were no significant differences for age (p = .521) or years since diagnosis (p = .984) 
between the subgroup used in this analysis (n = 26) and the overall group within the ‘Step it 
Up’ research study (n = 68) [29]. Participants daily and weekly mean steps and EE values are 
outlined in Table 1. The one-way repeated measures ANOVA indicated no significant 
difference in mean daily step count (F(6,144) = 1.483, p > 0.05) or mean daily EE (F(6,144) 
= .987, p > 0.05) across the consecutive 7-day period, regardless of whether they were 
weekend or week days.  
 
[Insert Table 1.] 
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There were no significant differences in mean daily step count or mean daily EE between 
participants with consecutive or non – consecutive data (Step count: t(49) = .01, p > 0.05, EE: 
t(49) = -0.45, p > 0.05). Therefore, Day 1 was representative of the first valid day of data, 
Day 2 the second day of valid data etc. Mean CoVw for daily step count was 27.1 % (SD = 
9.2 %; Range = 8.9 – 49.3 %), with mean CoVb = 47.9 % (SD = 5.6 %; Range = 41.2 – 57.0 
%). Mean CoVw for daily EE was 16.0 % (SD = 5.9 %; Range = 7.5 – 27.0 %), with mean 
CoVb = 23.6 % (SD = 6.1 %; Range = 19.0 – 37.1 %). Mean, median and range of ICC values 
for 1 day, 2 day, 3 day, 4 day, 5 day and 6 day combinations are outlined in Table 2.  
 
[Insert Table 2.] 
 
G-study results indicated that the majority of the variance in both mean daily step count and 
mean daily EE were as a result of variance within the participant term (67.5% and 48.8%), 
whilst the variance between days accounted for minimal variance in both mean daily step 
count (1.4%) and mean daily EE (11.0%) (Table 3). The remaining variance (31.1% for mean 
daily step count and 40.2% for mean daily EE) was due to the interaction effect between the 
participant and day terms and is deemed as non-specific variance.  
 
[Insert Table 3.] 
 
G-coefficients ranged from 0.68 – 0.94 for step count and 0.55 – 0.89 for EE. Step count 
derived from selecting any random single day (0.68) was the only combination, within the 
step count parameter, to fall below 0.80. Therefore, a minimum of any 2 days of the week (G-
coefficients ≥ 0.80) was indicated as a reliable estimate of mean daily step count. EE derived 
from selecting any random single day (0.55), any random 2-day combination (0.71) and any 
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random 3-day combination (0.79) fell below 0.80. Therefore, a minimum of any random 4-
day combination (G-coefficients ≥ 0.80) was indicated as a reliable estimate of mean daily 
EE (Figure 1). 
 
[Insert Figure 1.] 
 
Bland-Altman results indicate the greatest agreement between methods for both parameters 
(step count and EE) is any 6-day combinations versus the 7-day criterion, with a mean bias 
range of -171 to 177 for step count, and a mean bias range of -28 to 71 kcal for EE (Table 4). 
Ranges were represented as there were multiple results for each combination of days (single 
day = 7 results, 2 Day combinations = 21 results etc.). All combinations of days result in a 
mean bias within ± 10% when expressed as a percentage of the criterion, bar single day 
combinations. 
 
[Insert Table 4.] 
 
Discussion  
 
The aim of this study was to identify the minimum number of days needed to reliably 
estimate daily step count and daily EE, using the SWA, in an MS population who walk 
unaided. We found there was no significant difference when examining the effect of day type 
on daily step count or daily EE therefore used any combination of days from 7 days of 24 
hour monitoring in our analysis. The current research indicates a minimum of two days is 
necessary to reliably estimate daily step count and a minimum of any random 4-day 
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combination is necessary for a reliable estimate of daily EE in this ambulatory sample of 
people with MS. 
 
The finding that there was no effect of day type on daily step count is supported by previous 
research [23] which identified that day type had little effect on the reliability of calculating 
mean daily step count. Almeida, Wasko [37] also found no significant difference in total 
energy expenditure (TEE) due to day type, in women with rheumatoid arthritis, suggesting 
that participants did not undertake marked differences in PA during their weekend compared 
to their weekdays, due to a moderate level of disability. This may support that those with 
moderate disability due to a chronic disease display relatively consistent levels of PA, as 
identified by EE, step or activity count, across all days of the week [23]. 
 
Our finding for mean daily step count (8327) confirms the relative inactivity of this 
population and confirms that the patients in this analysis were representative of the wider MS 
population with a PDDS ≤ 3. Whilst participants recruited with the “Step it Up” research 
study were required to have a sedentary lifestyle, this was defined by the amount of time 
spent performing moderate to strenuous exercise. As mean daily step count within the current 
study was similar to that previously reported [25, 38], it appears people with MS, and a 
PDDS ≤ 3, may maintain a somewhat active profile, despite not engaging in higher intensity 
exercise. Mean daily EE calculated via the consecutive and non-consecutive 7-day criterion 
were also similar to those found when investigating daily TEE in other chronic disease 
populations such as diabetes and rheumatoid arthritis [37, 39].  
 
The key investigation in our research was to examine the minimum number of days needed to 
reliably estimate daily step count and daily EE using the SWA, in people with MS who walk 
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unaided as these are the target of health promoting PA interventions. The current research 
indicates a minimum of two days is necessary to reliably estimate daily step count. This was 
supported by both single day ICC values and the single day G – coefficient, as values fell 
below the  recommended 0.80 threshold [33]. This is in agreement with previous research  in 
older adults [40], however is in contrast to Motl, Zhu [23] who suggested a minimum of three 
days is required in an MS population and recruited an MS population whom performed gait 
with or without the use of a cane and utilised a pedometer for data collection. However, the 
participants in the current study all performed habitual walking behaviour unaided and a 
multisensory accelerometer based device was utilised for data collection. This may account 
for the contrast in results found.   
 
For EE, ICC results within the current study indicate a minimum of any random 2-day 
combination is needed for a reliable estimate of EE. This is supported within a diseased 
population where ICC values for a random single day compared to the 7-day criterion fell 
below 0.80, when monitoring daily TEE in women with rheumatoid arthritis [37]. However, 
on performing the generalisability theory analysis, G - coefficients from combinations less 
than 4 days fell below 0.80, indicating a minimum of any random 4-day combination is 
necessary for a reliable estimate of daily EE. The generalisability theory identifies where 
variance lies within the data, any variance interaction, and this is then factored into G-
coefficient calculation [41]. Also, the generalisability theory has previously been identified as 
superior to the ICC [41]. Therefore, within the current analysis G-coefficients were given 
more credence than ICC results and a minimum of any random 4-day combination was 
regarded as necessary for a reliable estimate of daily EE. Whilst there is limited research 
investigating the number of days required for a reliable estimate of EE in people with MS, 
this result is comparable to similar research performed within a healthy population (3-5 days 
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required to calculate a reliable estimate of mean daily EE) [42], and a population with chronic 
disease (4 days  required to calculate a reliable estimate of mean daily EE) [37].  
 
Lastly, Bland-Altman results indicated that all combinations of days, bar single day 
combinations, resulted in a mean bias of ≤ 10 % compared to the criterion 7-day mean, for 
both step count and EE. When guided by ICC and G-coefficient results selecting a 2–day 
combination for step count results in a 95% CI range of ± 1943 to ± 3342 steps, compared to 
the criterion 7-day mean, whilst for EE selecting a 4–day combination results in a 95% CI 
range of ± 158 to ± 313 kcal, compared to the criterion 7-day mean. Reliable step count 
devices have been identified to have a 95% CI of ±1801 steps over a three day period in those 
with a neurological condition [42] and therefore the results represented by the Bland-Altman 
analysis may be representative of the population.   
 
Study Limitations 
 
Whilst this study contributes significantly to the research questions posed by Motl, 
Learmonth [18] there are limitations. Firstly, our subgroup (n = 26) is smaller than that 
previously used in studies investigating PA and step count in people with MS [15, 22, 23]. 
Secondly, whilst our sub-group was representative of our larger group (n = 68) in terms of 
both age and years since diagnosis, it includes only those with minimal to moderate disability 
(PDDS ≤ 3). Further research should investigate the number of days necessary for a reliable 
estimate of step count, in people with MS with more activity limitations.   
 
 
Conclusions  
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It is vital that we are able to accurately quantify habitual walking behaviour and EE in people 
with MS, to gain a better understanding of the amount of PA this population undertakes on a 
daily basis. These results indicate that a minimum of 2 days for step count and a minimum 4 
days for EE, regardless of day type, is needed to reliably estimate daily values, using the 
SWA, in an MS population with unaided walking gait. This may minimise the number of data 
collection days required in future studies, when researching PA in people with MS utilising a 
24-hour activity monitor such as the SWA. This may not only reduce the burden placed upon 
participants, but also improve adherence within these studies.  
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Figure 1. G-coefficients (    ) and minimum ICC values ( x ) when comparing 1 – 7 day 
combinations to a 7–day mean for (a) mean daily step count and (b) mean daily EE. 
Dashed line represents a D-study coefficient of 0.80.  
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Table 1. Daily and weekly mean daily steps and mean daily EE for participants with 7 
consecutive valid days, Monday – Sunday (n = 25).  
 Steps (steps per day) EE (kcal per day) 
Monday 8,529 (3,854; 7,019 – 10,040) 2,271 (570; 2,048 – 2,494) 
Tuesday 8,377 (3,676; 6,935 – 9,816) 2,251 (593; 2,019 – 2.484) 
Wednesday 8,083 (4,243; 6,420 – 9,747) 2,182 (607; 1,944 – 2,420) 
Thursday 8,566 (3,574; 7,165 – 9,967) 2,265 (525; 2,060 – 2,471) 
Friday 8,420 (3,537; 7,033 – 9,807) 2,208 (666; 1,946 – 2,468) 
Saturday 9,008 (4,067; 7,413 – 10,602) 2,419 (559; 2,200 – 2,638) 
Sunday 7,304 (3,345; 5,993 – 8,615) 2,199 (358; 2,059 – 2,339) 
Week (all days) 8,327 (3,487; 7,077 – 9,576) 2,256 (421; 2,091 – 2,421) 
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Table 2. Intra-class correlation values for combinations of days (1-6) and the criterion 
7-day.  
  Step Count  Energy Expenditure 
Combinations 
of days 
 Mean 
 
Median Range  Mean Median Range 
1 Day  0.83 0.84 0.77 – 0.88  0.74 0.81 0.46 – 0.88 
2 Days  0.96 0.96 0.94 – 0.98  0.92 0.93 0.86 – 0.98 
3 Days  0.98 0.98 0.97 – 0.99  0.96 0.96 0.93 – 0.98 
4 Days  0.99 0.99 0.98 – 0.99  0.98 0.97 0.96 – 0.99 
5 Days  0.99 0.99 0.99 – 1.00  0.99 0.99 0.97 – 1.00 
6 Days  1.00 1.00 N/A  0.99 1.00 0.98 – 1.00 
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Table 3. G-Study results representing variance component estimates and relative 
magnitude of error for each term and the interaction effect. 
  Step Count Energy Expenditure 
Term  Variance 
Component 
Estimates 
Relative 
Magnitude 
of Error (%) 
Variance 
Component 
Estimates 
Relative 
Magnitude 
of Error (%) 
P  12,039,320.97 67.5 152,281.81 48.8 
D  243,365.11 1.4 34,533.74 11.0 
P X D  5,560,327.97 31.1 125,468.85 40.2 
Total  17,840,014.05 100 312,284.40 100 
P = participant term, D = day term, P X D = participant x day interaction effect 
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Table 4.  Range of Bland-Altman mean bias and range of 95% CI represented in steps 
and kcal for combinations of days (1-6) compared to the respective criterion 7-day mean 
for daily step count and mean daily EE.  
  Step Count 
(steps) 
 Energy Expenditure 
(kcal) 
Combinations 
of Days 
 Mean Bias 
Range 
(% of Criterion) 
95% CI Range 
(% of Criterion) 
 Mean Bias 
Range 
(% of Criterion) 
95% CI Range 
(% of Criterion) 
Single Day  -1062 to 1028 
(-12.1 to 11.7) 
± 3815 to ± 4865 
(± 43.6 to ± 55.6) 
 -425 to 169 
(-18.8 to 7.5) 
± 420 to ± 1000 
(± 18.6 to ± 44.3) 
2 Days  -751 to 798 
(-8.6 to 9.1) 
± 1943 to ± 3342 
(± 22.2 to ± 38.2) 
 -225 to 141 
(-10.0 to 6.2) 
± 219 to ± 602 
(± 9.7 to ± 26.7) 
3 Days  -565 to 551 
(-6.5 to 6.3) 
± 1416 to ± 2433 
(± 16.2 to ± 27.8) 
 -148 to 127 
(-6.5 to 5.6) 
± 211 to ± 418 
(± 9.3 to ± 18.5) 
4 Days  -414 to 423 
(-4.7 to 4.8) 
± 1062 to ± 1825 
(± 12.1 to ± 20.9) 
 -95 to 111 
(-4.2 to 4.9) 
± 158 to ± 313 
(± 7.0 to ± 13.9) 
5 Days  -319 to 300 
(-3.6 to 3.4) 
± 777 to ± 1337 
(± 8.9 to ± 15.3) 
 -56 to 90 
(-2.5 to 4.0) 
± 87 to ± 241 
(± 3.9 to ± 10.7) 
6 Days  -171 to 177 
(-2.0 to 2.0) 
± 636 to ± 811 
(± 7.3 to ± 9.3) 
 -28 to 71 
(-1.2 to 3.1) 
± 70 to ± 167 
(± 3.1 to ± 7.4) 
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